Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Anbio Biotechnology

NNNN ✓ COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Medical Equipment, Supplies & Distribution ·

USA Micro Cap Analyst: N/A

Last Close

$3.36

▼ -9.68%

Market Cap $147.47M · Vol 11.55K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

22.91

FWD: N/A

Market Cap

$147.47M

Micro Cap

Div Yield

N/A

EPS Growth

N/A

YoY

RSI (14)

30.77

Momentum

Beta

N/A

vs Market

52W High

$43.89

92.34% below

52W Low

$3.10

8.39% above

Volume

11.55K

Avg 15.40K

P/B

43.77

Price-to-book

ROE

N/A

Return on equity

Free Float

95.22%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Anbio Biotechnology (NNNN) stock is Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does NNNN pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-11.81%

-46.67%

-68.74%

-88.21%

YTD

-88.83%

-83.92%

N/A

Financials & Valuation

TTM · Annual

Total Revenue	$8.65M
Net Income	$6.40M
Revenue Growth (YoY)	N/A
Gross Margin	87.24%
Operating Margin	66.70%
Net Profit Margin	74.06%
ROE	N/A
ROA · ROIC	26.05% · 27.05%

P/E Ratio	22.91
Forward P/E (FY1)	N/A
PEG Ratio	1.27
P/S	151.87
P/B	43.77
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	43.89M

Technical Indicators

50-Day SMA	$5.47
200-Day SMA	$17.34
RSI (14)	30.77
Beta	N/A
52-Week High	$43.89
52-Week Low	$3.10

Volume Today	11.55K
Avg Daily Volume (30D)	15.40K
Relative Volume	0.75x
Volatility (10D)	90.66
Volatility (30D)	102.39
Free Float	95.22%

Analyst Consensus

N/A

Current Price $3.36

Mean Target N/A

52W Low$3.10 52W High$43.89

Current

Target

$3.10 $43.89

Current Analyst target

· 0 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG01RL0JQX1

ISINKYG0367B1059

CountryGermany

Sub-IndustryMedical Equipment, Supplies & Distribution (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

ABT Abbott Laboratories +1.56% MDT Medtronic PLC -0.59% COR Cencora, Inc. +0.09% 7741.T HOYA CORPORATION -0.46% BDX Becton Dickinson and Co -0.23%

Company Profile

Anbio Biotechnology is a Germany-based medical device company. The Company is engaged in the development of medical technology and the provision of in vitro diagnostics (IVD) products. Its products offer solutions for over the counter (OTC) use, point-of-care (POCT) settings, and laboratory applications, ensuring that both healthcare providers and patients have access to reliable and efficient diagnostic tools in any setting. Its IVD products detect a wide range of biomarkers across critical medical fields, including infectious diseases, cancer, cardiovascular diseases, inflammation, drug abuse, endocrine disorders, renal disease, pharmacogenomics, and diabetes. Some of its IVD platforms: Chemiluminescence Immunoassay (ChLIA), Lateral Flow Immunoassay (LFIA), Fluorescent Immunoassay (FIA), Polymerase Chain Reaction (PCR) and Loop-mediated Isothermal Amplification (LAMP).